(NICE) amended its guidelines by awarding special attention to interventions near the end of life. The amendment acknowledges that life and health might be valued more highly when life is more scarce, but is treated as a binary outcome ('end of life' or not).
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The amendments to NICE guidelines stated an 'end of life (EOL) criteria' for which interventions may be recommended for approval despite offering additional QALYs at a cost greater than £30,000 per QALY. NICE Committees now consider the following criteria: the patient has less than 24 months' life-expectancy, there is sufficient evidence to show that the new intervention provides at least three additional months of life-expectancy and the intervention is expected to be taken up by a small patient population (NICE, 2009 ). This guideline change has effectively led to a tiered cost-effectiveness threshold with evidence satisfying all criteria reportedly judged against a higher value.
The main aim of this study was to elicit public preferences at a small, pilot level regarding life extensions near the end of life to provide evidence showing survival gains to be valued either equally or differentially with proximity to the end of life. The respondents were given the task of imagining themselves as patients in scenarios A and B and choosing which treatment they felt provided a better improvement. It was made clear that the respondent should not automatically choose the option that provided the longest life after treatment without giving consideration to the respective initial life-endowments. They were therefore asked to choose which of the two gains they deemed to be most valuable. They could either express a preference or explicitly state indifference.
BACKGROUND AND OBJECTIVES
Statistical analysis -Since the sample size was small, the non-parametric Wilcoxon signedranks test was used to analyse the data. The null hypothesis is: There is no statistically significant variation between the magnitude of gain in Scenario A and that in Scenario B which provides indifference between the two, i.e. G B =G A .
Life expectancy matrix (LEM) -Using a 'life-years before treatment' vs. 'life-years after treatment' framework provides an indifference set, a line upon which no point is any more or less preferred to the other.
The 45 lines on the LEM can be viewed as indifference curves abiding by the assumption that "a QALY is a QALY is a QALY" (Figure 2 ). Having one year to live before treatment, on the yaxis, and one year after treatment on the x-axis, provides no gain for the recipient.
The rightmost points of the 45 lines are the reference points of the survey to which the four indifference curves will be connected. If these indifference curves were observed to 'fan out' A QALY 'weighting factor' was calculated by taking the gain in Scenario B as a proportion of the gain in Scenario A, then the ratios were averaged for each question to give a mean ratio.
The inverse of the ratios provides a 'weighting factor'. Weights decrease as initial life-years approach 4 years where they are assumed to take a value of 1 (initial life endowment 0.25, 1, 2, 3, respective weighting factors 1.846, 1.5, 1.54, 1.075). As such, adjusting a QALY gained by its corresponding weight would increase its value relative to a QALY gained beyond an initial endowment of 4 years.
The results suggest a more refined recognition of EOL care than current NICE practice. The QALY weights provide no need to place a variable monetary value on QALYs instead, the QALY is adjusted to take into account how close the patient is to EOL. Based upon these results, a patient with one year left to live would have all potential QALY gains increased by a factor of 1.500. A gain of two months, which would be rejected for special consideration by NICE's current EOL criteria, would be increased to an effective three months, improving its cost-effectiveness ratio. This new measure -the quality and remaining-life adjusted year, or QARLY -offers a more refined sliding scale, 'stepping' down towards one at higher initial lifeyears.
